Latest Japanese Market News

Lynas Rare Earths delivered a record A$977.9 million revenue and A$222.4 million net profit in FY26, underpinned by strong rare earth production, strategic supply agreements, and a 10-year Malaysian licence renewal.

Hazer Group and KBR have secured a paid pre-feasibility study with a leading Japanese power utility to explore large-scale deployment of methane pyrolysis technology, reinforcing Hazer's foothold in Japan's clean hydrogen market.

Talga Group has signed a non-binding Letter of Intent with Japan’s Dainen Materials to supply its Talnode®-C battery anode from Sweden, aiming for a binding agreement by year-end. This deepens a five-year partnership and positions Talga in Japan’s demanding battery market.

Lynas Rare Earths reported a record A$265 million quarterly revenue in Q3 FY26, driven by higher NdPr prices and production milestones including early Samarium oxide output. The company secured a 10-year Malaysian operating licence and extended a key supply deal with Japanese partner JARE through 2038.

Bio-Gene has signed a term sheet with Sumitomo Corporation and Nakashima Trading to introduce its 100% natural insecticide Qcide® to Japan’s $1 billion household pest market, aiming for a late 2026 launch.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

New Hope Corporation reported a 4.8% rise in coal production and an 8.2% increase in sales for the January quarter, maintaining steady earnings and reducing capital expenditure guidance amid improving logistics and operational resilience.

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

icetana Limited reports its strongest quarterly growth yet, driven by a strategic partnership with SoftBank Robotics that has propelled annual recurring revenue to $2.3 million.

Pinnacle Investment Management has secured a strategic foothold in Japan’s private markets by acquiring up to 13% of Advantage Partners, complementing its strong FY25 growth and global expansion ambitions.

Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.

Straker Ltd has reported a record adjusted EBITDA of NZ$4.8 million for FY25, driven by strong growth in AI subscription services and operational efficiencies, even as overall revenue declined 10.3%. The company’s strategic pivot towards AI-powered offerings signals a promising shift in its business model.